Panacea Biotec
Ticker > Company >

Panacea Biotec share price

Panacea Biotec Ltd.

NSE: PANACEABIO BSE: 531349 SECTOR: Pharmaceuticals & Drugs  54.35 K   112   24

458.65
+24.15 (5.56%)
NSE: Today, 12:54 PM

Price Summary

Today's High

₹ 474.25

Today's Low

₹ 433.8

52 Week High

₹ 581.9

52 Week Low

₹ 259.7

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 2809.27 Cr.

Enterprise Value

₹ 2904.7 Cr.

No. of Shares

6.13 Cr.

P/E

0

P/B

9.14

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  50.17

CASH

₹ 29.44 Cr.

DEBT

₹ 124.87 Cr.

Promoter Holding

72.48 %

EPS (TTM)

₹  -1.33

Sales Growth

39.89%

ROE

1.08 %

ROCE

4.08%

Profit Growth

104.06 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year39.89%
3 Year1.53%
5 Year-4.14%

Profit Growth

1 Year104.06%
3 Year30.96%
5 Year-33.14%

ROE%

1 Year1.08%
3 Year-14.27%
5 Year-13.77%

ROCE %

1 Year4.08%
3 Year-7.81%
5 Year-4.61%

Debt/Equity

0.3794

Price to Cash Flow

75.37

Interest Cover Ratio

1.3052

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 72.48 0.00
Mar 2025 72.48 0.00
Dec 2024 72.49 0.00
Sep 2024 72.87 0.00
Jun 2024 73.46 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of -199.0808 days.
  • The company has a high promoter holding of 72.48%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 18.6757297423944.

 Limitations

  • The company has shown a poor revenue growth of 1.53349770699727% for the Past 3 years.
  • Company has a poor ROE of -14.274393209569% over the past 3 years.
  • Company has a poor ROCE of -7.80721170480353% over the past 3 years
  • Company has contingent liabilities of 369.385 Cr.
  • The company has a low EBITDA margin of -9.78410222312693% over the past 5 years.
  • The company is trading at a high PE of 0.
  • The company is trading at a high EV/EBITDA of 162.1252.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 56.88 76.64 108.43 67.9 112.25
Total Expenditure 67.37 69.9 93.04 86.47 115.27
Operating Profit -10.49 6.74 15.39 -18.57 -3.02
Other Income 3.8 3.41 3.32 6.09 4.95
Interest 3.21 3.76 3.85 4.64 6
Depreciation 5.08 5.09 5.21 4.91 4.77
Exceptional Items 0 0 0 0 0
Profit Before Tax -14.98 1.3 9.65 -22.03 -8.84
Tax -1.2 0.01 0 -9.64 -2.14
Profit After Tax -13.78 1.29 9.65 -12.39 -6.7
Adjusted EPS (Rs) -2.25 0.21 1.57 -2.02 -1.09

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 489.68 343.56 235.5 257.07 359.6
Total Expenditure 479.63 343.07 308.17 319.69 345.44
Operating Profit 10.05 0.49 -72.67 -62.63 14.17
Other Income 43.91 20.75 12.57 34.44 24.91
Interest 147.25 7.52 7.04 10.06 13.78
Depreciation 27.29 26.57 26.43 24.5 21.09
Exceptional Items -15.4 0 0 0 0
Profit Before Tax -135.97 -12.85 -93.58 -62.75 4.21
Tax 17.1 1.56 0 24.79 0.66
Net Profit -153.07 -14.44 -93.58 -87.54 3.55
Adjusted EPS (Rs.) -24.99 -2.35 -15.28 -14.29 0.58

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 6.13 6.13 6.13 6.13 6.13
Total Reserves 886.61 502.04 408.97 319.53 323.02
Borrowings 60.43 62.08 84.1 102.4 124.87
Other N/C liabilities 186.72 191.99 187.36 214.38 222.12
Current liabilities 167.35 197.67 244.16 250.85 248.99
Total Liabilities 1307.23 961.76 933.31 895.38 925.12
Assets
Net Block 447.29 398.44 416.13 385.31 357.26
Capital WIP 3.66 12.93 0.86 16.42 70.8
Intangible WIP 0.08 0.04 0.01 11.42 25.74
Investments 2.55 0.27 0.27 0.27 0.27
Loans & Advances 186.5 187.45 188.82 225.33 221.39
Other N/C Assets 52.84 106.82 78.38 57.48 66.46
Current Assets 614.32 255.8 248.83 199.13 183.2
Total Assets 1307.23 961.76 933.31 895.38 925.12
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -135.97 -12.88 -93.58 -62.75 4.21
Adjustment 204.95 31.82 35.98 10.43 30.95
Changes in Assets & Liabilities -143.93 20.3 5.73 42.67 4
Tax Paid -7.9 -0.98 -0.82 -1.09 -1.88
Operating Cash Flow -82.86 38.27 -52.69 -10.74 37.27
Investing Cash Flow -16.58 -37.32 39.54 2.41 -51.01
Financing Cash Flow 109.39 -7.2 9.83 9.01 12.82
Net Cash Flow 9.96 -6.26 -3.32 0.67 -0.91

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 73.46 72.87 72.49 72.48 72.48
dr. rajesh jain 49.33 49.33 49.33 49.33 49.33
first lucre partnership c... 3.68 3.68 3.68 3.68 3.68
mr. sandeep jain 16.25 15.66 15.28 15.27 15.27
mrs. nirmala jain 4.10 4.10 4.10 4.10 4.10
second lucre partnership ... 0.09 0.09 0.09 0.09 0.09
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 26.54 27.13 27.51 27.52 27.52
investor education and pr... 0.17 - 0.17 - 0.17
investor education and pr... - 0.17 - 0.17 -
magic square hospitality ... - 2.68 2.18 - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q1FY22

Company News

Panacea Biotec - Quaterly Results 14 Aug, 6:25 PM Panacea Biotec - Quaterly Results 14 Aug, 6:25 PM Panacea Biotec - Quaterly Results 30 May, 8:22 PM Panacea Biotec - Quaterly Results 30 May, 8:22 PM Panacea Biotec bags additional order from UNICEF 24 Apr, 10:22 AM Panacea Biotec informs about cessation of senior management personnel 1 Apr, 11:05 AM Panacea Biotec - Quaterly Results 14 Feb, 6:42 PM Panacea Biotec - Quaterly Results 14 Feb, 6:42 PM Panacea Biotec informs about board meeting 31 Jan, 4:50 PM Panacea Biotec’s arm launches baby diapers, wipes under ‘NikoMom’ brand 3 Jan, 6:33 PM Panacea Biotec informs about disclosure 28 Dec, 3:08 PM Panacea Biotec’s arm makes further investment in Panacea Biotec Inc 28 Dec, 2:12 PM Panacea Biotec gets LoA from UNICEF 26 Dec, 11:39 AM Panacea Biotec informs about press release 12 Sep, 5:00 PM Panacea Biotec informs about disclosures 9 Sep, 2:25 PM Panacea Biotec informs about disclosure 20 Aug, 12:09 PM Panacea Biotec informs about newspaper publication 16 Aug, 12:30 PM Panacea Biotec - Quaterly Results 14 Aug, 4:25 PM Panacea Biotec’s arm incorporates wholly-owned subsidiary in USA 24 Jun, 9:59 AM Panacea Biotec informs about demat status report 7 Jun, 4:46 PM Panacea Biotec - Quaterly Results 30 May, 2:22 PM Panacea Biotec informs about details of shares dematerialized 5 Apr, 4:50 PM Panacea Biotec informs about newspaper publication 13 Mar, 5:07 PM Panacea Biotec informs about notice of postal ballot 12 Mar, 5:19 PM Panacea Biotec - Quaterly Results 13 Feb, 2:50 PM Panacea Biotec - Quaterly Results 13 Feb, 2:50 PM Panacea Biotec - Quaterly Results 13 Feb, 2:50 PM Panacea Biotec informs about board meeting 30 Jan, 4:41 PM Panacea Biotec launches fully-liquid wP-IPV based Pentavalent vaccine ‘EasyFourPol’ 14 Dec, 6:16 PM Panacea Biotec’s arm launches Paclitaxel Protein-Bound Particles for Injectable Suspension 28 Oct, 11:33 AM Panacea Biotec informs about updates 28 Oct, 10:36 AM USFDA concludes inspection at Baddi facility of Panacea Biotec’s arm 13 Oct, 10:09 AM Panacea Biotec informs about disclosure 12 Sep, 5:26 PM Panacea Biotec informs about BRSR 7 Sep, 4:53 PM Panacea Biotec informs about shares dematerialized 6 Sep, 12:37 PM Panacea Biotec - Quaterly Results 12 Aug, 3:17 PM Panacea Biotec - Quaterly Results 12 Aug, 3:17 PM Panacea Biotec informs about launch of news products 15 Jun, 2:24 PM Panacea Biotec’s arm launches new range of pediatric food & nutritional products 15 Jun, 11:40 AM Panacea Biotec - Quaterly Results 30 May, 2:53 PM Panacea Biotec informs about closure of trading window 30 Mar, 11:21 AM Panacea Biotec - Quaterly Results 14 Feb, 1:43 PM Panacea Biotec - Quaterly Results 14 Feb, 1:43 PM Panacea Biotec - Quaterly Results 14 Feb, 1:43 PM Panacea Biotec donates 125,000 SDVs to Cuba 17 Jan, 12:50 PM Panacea Biotec informs about disclosure of related party transactions 29 Nov, 3:43 PM Panacea Biotec - Quaterly Results 14 Nov, 4:54 PM Panacea Biotec - Quaterly Results 14 Nov, 4:54 PM Panacea Biotec gets UNICEF, PAHO awards for supply of Pentavalent Vaccine 11 Oct, 9:38 AM Panacea Biotec - Quaterly Results 9 Aug, 3:30 PM

Panacea Biotec Stock Price Analysis and Quick Research Report. Is Panacea Biotec an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Panacea Biotec. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Panacea Biotec has a PE ratio of -326.544416052908 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Panacea Biotec has ROA of 0.39% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Panacea Biotec has a Current ratio of 0.7358.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Panacea Biotec has a ROE of 1.0843%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Panacea Biotec has a Debt to Equity ratio of 0.3794 which means that the company has low proportion of debt in its capital.

  • Sales growth: Panacea Biotec has reported revenue growth of 39.8873% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Panacea Biotec for the current financial year is 3.93961135026306%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Panacea Biotec is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Panacea Biotec is Rs -1.3306. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Panacea Biotec in Ticker for free. Also, one can get the intrinsic value of Panacea Biotec by using Valuation Calculators, which are available with a Finology ONE subscription. 

Panacea Biotec FAQs

Q1. What is Panacea Biotec share price today?
Ans: The current share price of Panacea Biotec is Rs 434.5.

Q2. What is the market capitalisation of Panacea Biotec?
Ans: Panacea Biotec has a market capitalisation of Rs 2661.3449137 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Panacea Biotec?
Ans: The PE ratio of Panacea Biotec is -326.544416052908 and the P/B ratio of Panacea Biotec is 8.66140005701175, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Panacea Biotec share?
Ans: The 52-week high share price of Panacea Biotec is Rs 581.9, and the 52-week low share price of Panacea Biotec is Rs 259.7.

Q5. Does Panacea Biotec pay dividends?
Ans: Currently, Panacea Biotec does not pay dividends. Dividend yield of Panacea Biotec is around 0%.

Q6. What are the face value and book value of Panacea Biotec shares?
Ans: The face value of Panacea Biotec shares is Rs 1, while the book value per share of Panacea Biotec is around Rs 50.1651. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Panacea Biotec?
Ans: Panacea Biotec has a total debt of Rs 124.867 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Panacea Biotec?
Ans: The ROE of Panacea Biotec is 1.0843% and ROCE of Panacea Biotec is 4.0782%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Panacea Biotec a good buy for the long term?
Ans: The Panacea Biotec long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Panacea Biotec undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Panacea Biotec appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Panacea Biotec’s financials?
Ans: You can review Panacea Biotec’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Panacea Biotec

Panacea Biotec Limited Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Panacea Biotec Limited is a leading biotechnology company based in India. With a focus on healthcare and pharmaceuticals, the company has a strong presence in research, development, manufacturing, and marketing of vaccines, generics, and biopharmaceuticals. Panacea Biotec Limited aims to provide affordable healthcare solutions for patients around the world.

Panacea Biotec Limited - Share Price

Stay updated on the latest share price of Panacea Biotec Limited by visiting our stock analysis page. Our website provides real-time stock prices, allowing investors to track the performance of the company's shares.

Panacea Biotec Limited - Balance Sheet

To gain insight into the financial position of Panacea Biotec Limited, utilize our pre-built screening tools available on our website. These tools enable long-term stock investors to analyze the company's balance sheet. Additionally, through our premium features, investors can make use of fair value calculation tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Panacea Biotec Limited - Annual Report

The annual reports of Panacea Biotec Limited can be found as downloadable documents on our website. These reports provide comprehensive information about the company's performance, financials, operational highlights, and future prospects. Long-term stock investors can closely examine these reports to make informed investment decisions.

Panacea Biotec Limited - Dividend

For dividend analysis of Panacea Biotec Limited, our website provides access to dividend data and historical records. Investors can evaluate the company's dividend history to understand its dividend-paying practices and assess the potential income generated from their investments.

Panacea Biotec Limited - Quarterly Results

Along with the annual reports, we offer quarterly results of Panacea Biotec Limited for download on our website. These reports give investors a timely overview of the company's performance during specific quarters. Combined with our premium features, investors can use various analysis tools to gain deeper insights into the company's financial health.

Panacea Biotec Limited - Stock Price

On our website, you can find the latest stock prices of Panacea Biotec Limited, enabling you to closely monitor the price movements of the company's shares. Stay updated with real-time price data to make well-informed investment decisions.

Panacea Biotec Limited - Price Chart

Utilize the price charts available on our website to visualize the historical price movements of Panacea Biotec Limited's stocks. These charts help investors identify patterns and trends, enabling them to make more accurate predictions about future stock performance.

Panacea Biotec Limited - News

For the latest company news and updates about Panacea Biotec Limited, visit our website. Stay informed about significant developments, such as product launches, regulatory approvals, collaborations, and acquisitions, which may impact the company's stock performance.

Panacea Biotec Limited - Concall Transcripts

At our website, we provide downloadable concall transcripts of Panacea Biotec Limited. These transcripts contain records of the company's conference calls with analysts and investors, showcasing discussions on various aspects of the company's performance, strategies, and future plans.

Panacea Biotec Limited - Investor Presentations

Gain a deeper understanding of Panacea Biotec Limited's business strategies, growth plans, and market positioning by accessing investor presentations on our website. These presentations provide valuable insights into the company's operations, performance highlights, and future outlook.

Panacea Biotec Limited - Promoters

Panacea Biotec Limited is driven by a team of dedicated promoters who are professionals in the field of biotechnology and healthcare. Our website provides detailed information about the company's promoters, their expertise, and their contributions towards the company's growth.

Panacea Biotec Limited - Shareholders

Discover the major shareholders of Panacea Biotec Limited on our website. We offer insights into institutional investors and their holdings, helping investors understand the ownership structure of the company and its potential impact on stock performance.

By utilizing our website's comprehensive stock analysis tools and accessing downloadable reports, transcripts, and presentations, long-term stock investors can perform a detailed analysis of Panacea Biotec Limited. Stay informed, make informed investment decisions, and potentially benefit from the growth and prospects of this leading biotechnology company.

Read More
X